Video

How Important are Patient-Reported Outcomes in Pediatric Rheumatology?

Author(s):

Janet E McDonagh, MD, FRCP explains the importance of obtaining both the patient and parent perspective in pediatric rheumatology.

In the first part of our 3-part feature on patient-reported outcome measures (PROMs), Rheumatology Network interviewed pediatric rheumatologist, Janet E McDonagh, MD, FRCP to discuss the importance of obtaining both the patient and parent perspective. McDonagh is the Clinical Senior lecturer in Pediatric and Adolescent Rheumatology at the University of Manchester.

Too often, the opinion of the patient is overlooked because the parent is given the PRO questionnaire. In previous studies, investigators discovered that 50% of patients and parents disagreed with a patient’s quality of life, with 25% overestimating disability and pain and 25% underestimating these measures. Unfortunately, the wider the discrepancy is, the higher the risk of mental health issues. McDonagh tries to minimize this issue by giving the questionnaires to both parent and child at the same time to eliminate the chance that the parent will fill out the form on behalf of the patient. This also allows her to obtain twice the perspectives.

Further, McDonagh calls for a change in the way that PRO questionnaires are created. “I think any patient-reported outcome questionnaire should be developed with young people first and foremost. It should not be developed by doctors or researchers. It needs to be done with young people, not just parents, because we need to be asking what matters to them. And what matters to young people doesn't always matter to parents,” McDonagh stated. “I've been involved in some other specialties. In hemophilia, they created a patient-reported outcome involving young people, which was great. Specifically with pediatric rheumatology, the child is the patient. The parent can fill out the forms that they want to fill out, but it might not align with the child. Both are important perspectives. They're not wrong, but it's just different perspectives.”

Related Videos
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
Søren Andreas Just, MD, PhD: Developing AI to Mitigate Rheumatologist Shortages for Disease Assessment
Shreena K. Gandhi, MBBS: Recognizing Fibromyalgia as a Continuous Variable, Trait Diagnosis
Reducing Treatment Burden of Pegloticase for Uncontrolled Gout, with Orrin Troum, MD
Exploring CAR T-cell Therapy for Rheumatic/Autoimmune Diseases With Georg Schett, MD
John Stone, MD, MPH: Inebilizumab Efficacious for IgG4-Related Disease in MITIGATE Study
Uncovering the Role of COVID-19 in Rheumatic Disease, with Leonard Calabrese, DO
© 2024 MJH Life Sciences

All rights reserved.